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Abstract 
Review on ATP5B, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: ATPMB, ATPSB, HEL-S-271 
HGNC (Hugo): ATP5B 
Location: 12q13.3 
DNA/RNA 
Description 
The human ATP5B gene is located on the minus 
strand and spans 7894 bps of genomic region 
(56638175 - 56646068). ATP5B gene sequence 
shows partial homology with chromosomes 2 and 
17. There are 13 Alu repeat sequences. Among these
sequences, 4 were found to be inside the intron and 
the rest were towards the upstream side. 
Figure 1. A. Location of ATP5B gene and the representation of its transcript. ATP5B gene is localized on 12q13.13 on minus 
strand and contains exonic regions. B. Location of ATP5BP1 (ATP synthase, H+ transporting, mitochondrial F1 complex, beta 
polypepide pseudogene 1) and pseudogene. 
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Figure 2. ATP5B protein sequence data showing beta-barrel domain (brown colored), nucleotide binding domain (blue colored), 
C terminal domain (green colored), Walker A motif (light pink), Walker B motif (orange colored), polypeptide binding site (black), 
ATP binding site (chemical binding) (red colored), inhibitor binding site (dark pink). 
 
 
ATP5B gene consists of four "CCAAT" sequences 
upstream and these sequences are much closer to the 
transcriptional initiation site (Neckelmann et al., 
1989). 
This gene encodes a single transcript as presented in 
NCBI database. It has 10 exons and mRNA size 
1857 bp. It has 529 amino acids (aa) and its size is 
about 56 kDa (figure 1A). 
Transcription 
ATP5B gene transcript is assigned in the reference 
database as well as ensemble data base including 11 
splice variants which are described as 
ENST00000262030, ENST00000552959, 
ENST00000551020, ENST00000553007, 
ENST00000551570, ENST00000550162, 
ENST00000547250, ENST00000547808, 
ENST00000548647, ENST00000551182, 
ENST00000548474. The level of mRNA transcript 
reveals marked differences between tissues. It is 
mostly expressed in the heart while it is less 
expressed in the skeletal muscles. It is also less 
expressed in liver and kidney. These findings 
suggest that tissue-specific mRNA levels of ATP5B 
can occur with transcriptional control (Neckelmann 
et al., 1989). The exact function of ATP5B is not 
known and the level of ATP5B gene expression has 
been shown to fall in different human tumors as 
compared to normal tissues (Willers et al., 2010). 
ATP5B transcripts were found to be highly 
expressed in colorectal cancer patients (Geyik et al., 
2014). 
Pseudogene 
A pseudogene named ATP5BP1 has been found on 
chromosome number 2 with contig number 
NC_000002.12 (reference GRCh38 Primary 
Assembly) for ATP5B gene. This pseudogene is 
encoded in the intronic region of the VWA3B gene. 
It is localized on 2q11.2 and is also known by other 
terms like ATP5BL1; ATPMBL1; ATPSBL. It is 
1783 nt in length (figure 1B). 
Protein 
Description 
ATP synthase beta subunit which is ATP5B protein 
and is also known as mitochondrial precursor is 
encoded by ATP5B gene. During oxidative 
phosphorylation, it maintains the electrochemical 
tendency of the protons in the membrane as well as 
it possess 5 sub units of ATP synthase enzyme like 
alpha (α), beta (β), gamma (γ), delta (Δ) and epsilon 
(ε) which acts as a catalyst in ATP synthesis. ATP5B 
constitutes the beta-subunit of ATP synthase enzyme 
and this enzyme is formed of 529 amino acid 
residues. Figure 2 shows that the molecular weight 
of this protein is 56559.90 g/mol and isoelectric 
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point is 5.0668. The amino acid sequence of this 
protein and domain are also shown. 
ATP5B protein is composed of three domains: ATP 
synthase alpha/beta family, beta-barrel domain (63-
129 aa), F1 ATP synthase beta subunit nucleotide 
binding domain (131-420 aa), ATP synthase 
alpha/beta chain C-terminal domain (418-525 aa). It 
consists of a large family of proteins consisting of 
ATP-binding cassette transporter nucleotide-binding 
domains; ABC transporters, ions, sugar and different 
components transporting peptides and organic 
molecules. This nucleotide binding domain 
resembles to all other members of this family 
protein. It consists of ABC transporter, the Q-loop, 
and H-loop/switch region and in addition consists of 
a subset of nucleotide hydralazine motifs such as 
Walker A motif/P-loop and Walker B motifs that are 
mainly found in many hydrolysis proteins and 
several ATP and GTP-binding proteins. 
Expression 
In oxidative phosphorylation, the cellular relative 
expression level of ATP5B protein was compared 
between normal and tumor tissues. It has been 
reported that there was less expression in tumor 
tissues as compared to normal (Cuezva et al., 2004). 
ATP5B gets down regulated in some cancers and 
helps to increase the expression of some glycolytic 
pathway markers. The cell death response with 
chemical agents shows correlation with oxidative 
phosphorylation as well as ATP5B expression 
(Cuezva et al., 2009; Lin et al., 2008; Shin et al., 
2005). ATP5B expression was found to be 
significantly lower in esophageal and breast cancer 
cells as compared to normal tissues (Acebo et al., 
2009). ATP5B protein expression in the cancer 
tissue was found to be down-regulated as compared 
to normal tissues (Cuezva et al., 2002; López-Ríos et 
al., 2007; Willers et al., 2010). The mitochondrial 
localization and translation of β-F1-ATPase mRNA 
(termed β-mRNA) are known to be primary sites for 
regulating the spatial and temporal expression of the 
protein as it is indicated by the expression of β-F1-
ATPase in the liver, in brown adipose tissue and 
during cell cycle progression. 
Localisation 
The ATP5B protein is localized to the 
mitochondrion inner membrane. 
Function 
As many other proteins, ATP5B has ATP and 
protein binding functions. The majority of cellular 
energy is synthesized in the form of ATP by ATP 
synthase. The force for ATP synthesis eventually 
comes from Na+ gradient which further activates an 
electrochemical proton rotation which takes place 
around F0 motor particles in the membrane.  
The effective rotation does not only require 
DeltamuH(+), membrane containing the potentials 
(Deltapsi) and proton concentration gradient 
(DeltapH) but also requires high proton 
concentration from the P sources (Von Ballmoos et 
al., 2009). 
The enzyme catalyzed oxidation of metabolic 
substances like glucose, fatty acids and amino acids 
are transferred to electron carriers.  
These electrons are then transferred to the electron 
transport system (ETS) located in the mitochondrial 
membrane. ATP synthase enzyme gets activated 
with the resulting proton gradient.  
ATP synthesis takes place by F0-F1 ATP synthase 
enzyme complex as a result of power produced by 
protons in the matrix.  
ATP5B protein also plays an important role in the 
oxidative phosphorylation during the formation of 
beta subunit of F1 unit of ATP synthase enzyme. 
In an study conducted with human 
immunodeficiency virus (HIV)-1, replication was 
found to be inhibited in HeLa P4 / R5 cells after the 
siRNA mediated knockdown of ATP5B (Zhou et al., 
2008). ATP5B was shown to be upregulated by Tat 
protein of HIV-1 virus (López-Huertas et al., 2013).  
ATP5B protein was also shown to be physically 
interacted with Vpr, a HIV-1 virus protein in 
HEK293 cells (Barrero et al., 2013). 
Metabolic changes are common characteristic 
features of cancer tissues.  
The downregulation of oxidative phosphorylation is 
a distinguishing feature of many cancer types.  
The decrease in expression of subunit of F1 unit of 
ATP synthase enzyme has been associated with 
many malignant cancers (Xiao et al., 2013). 
Angiostatin which is an angiogenesis inhibitor binds 
to ATP synthase found on endothelial cell surface 
and inhibits it.  
It also regulates cellular pH in cell acidosis and 
impairs endothelial cell formation.  
The agonist of ATP synthase MAb3D5AB1, 
recognizes catalytic β-subunit of ATP synthase and 
inhibits the activity of F1 domain (Chi et al., 2007). 
Mab3d5ab1 shows angiostatin-like properties and 
can be useful in the chemotherapy (Chi et al., 2007). 
Homology 
ATP5B gene sequence shows homology to 
chromosomes 2 of 17 (Neckelmann et al., 1989). It 
also shows homology to other organisms in 
following manner.  
It shows homology to P. troglodytes 99%, M.mullata 
98%, C. lupus 92%, M. musculus 89%, R. 
norvegicus 89%, G. gallus 78%, D. melanogaster 
74%, C. elegans, 70%, S. cerevisiae 69% (data from 
NCBI BLAST). 
Mutations 
There has been no mutation identified in ATP5B till 
now. However, many variations have been identified 
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on these genes: approximately 190 single nucleotide 
variant, 35 missense variant, 20 synonyms variant, 
110 intron variant, 11 deletion, 8 insertion, 1 indel, 1 
splice donor variant, 3 5'UTR variant, 6 3' UTR 
variant. 
Implicated in 
Colorectal cancer 
Prognosis 
Many studies show low expression of mitochondrial 
ATP synthase in many cancers including lung 
cancer, breast cancer and colorectal cancer (Willers 
et al., 2010).  
In addition, shorter life span of colorectal cancer 
patients has been associated with the low expression 
of ATP5B gene.  
In a study on colorectal cancer patients, ATP5B 
expression was found to be increased in tumor 
tissues as compared to normal ones and a significant 
increase in ATP5B gene expression was found in 
patients under 45 years of age (Geyik et al., 2014). 
Breast cancer 
Prognosis 
Breast cancer is a common malignancy in women 
worldwide.  
ATP5B was found to be upregulated in breast cancer 
tissues in a significant manner.  
This protein can even play an important role as a 
target protein in the treatment of cancers. Using ATP 
synthase inhibitor aurovertin B, in breast cancer cells 
MCF-7, the effect of ATP5B protein in tumor 
progression was found to be reduced (Huang et al., 
2008). 
Lung cancer 
Prognosis 
Using proteomic technologies, ATP5B has been 
found to be associated with McAb4E7 antigen. In an 
immunohistochemical study, an abnormal 
expression has been shown in non-small cell lung 
cancer (NSCLC) with McAb4E7 antigen on the cell 
membrane of tumors but such expression has not 
been shown in small cell lung cancer (SCLC). 
Through this particular study, the abnormal 
expression of ATP5B protein on cell surface can be 
presented as a potential tumor associated antigen in 
immunodiagnostic and immunotherapy for NSCLC. 
ATP5B may be a potential marker and a therapeutic 
target for immunotherapy in NSCLC on cell surface 
(Lu et al., 2009). 
Hepatocellular cancer 
Prognosis 
β-F1-ATPase is known to be a high-density 
lipoprotein (HDL) receptor for apolipoprotein A-I 
and is localized on the plasma membrane of rat and 
human hepatocytes and HepG2 cells (Martinez et al., 
2003). The expression of ATP5B is controlled 
during post-transcriptional level of cell cycle and 
oncogenesis. MiR-127-5p 3'UTR of β-F1-ATPase 
which shows much expression in fetal liver targets 
mRNA (β-mRNA). ATP5B expression is reduced in 
many types of cancer, but miR-127-5p does not 
show expression in some cancers. miR-127-5p has 
an important role in regulating the activity of 
mitochondrial bioenergetics in cancers (Izquierdo 
and Cuezva, 1997). ATP5B expression in the liver 
has been shown to be controlled at the post-
transcriptional level, and this control was found to be 
induced by miR-127-5p. miR-127-5p inhibits β-F1-
ATPase mRNA translation in humans (Willers et al., 
2012). 
Acute myeloid leukemia 
Prognosis 
ATP5B gene expression and ATP synthase activity 
was found to be downregulated in patients with acute 
myeloid leukemia (AML). The decline in the activity 
of the ATP synthase and the downregulation of 
ATP5B shows a positive correlation to Adriamycin 
resistance in primary leukemia cells (Li et al., 2009). 
ATP5B has been shown to play an important role in 
multi-drug resistance mechanism in relapsed or 
refractory showing AML patients (Xiao et al., 2013). 
The upregulation of ATP5B was found to inhibit 
growth of adriamycin induced leukemia cells and 
was also found to decrease resistance for adriamycin 
triggered apoptosis (Xiao et al., 2013). 
Other disease 
ATP5B gene has been also found to be associated 
with Alzheimer, Parkinson and Huntington disease. 
ATP5B and MDH1 were found to be involved in the 
energy metabolism, whose overexpression in null 
cell adenomas pave a new way of exploring the 
oncogenesis of these tumors (Hu et al., 2007). 
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